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Abstract
Background: Elevated levels of FMR1 mRNA in blood have been implicated in RNA toxicity associated with a number of clinical
conditions. Due to the extensive inter-sample variation in the time lapse between the blood collection and RNA extraction in
clinical practice, the resulting variation in mRNA quality significantly confounds mRNA analysis by real-time PCR.
Methods: Here, we developed an improved method to normalize for mRNA degradation in a sample set with large variation
in rRNA quality, without sample omission. Initially, RNA samples were artificially degraded, and analyzed using capillary
electrophoresis and real-time PCR standard curve method, with the aim of defining the best predictors of total RNA and mRNA
degradation.
Results: We found that: (i) the 28S:18S ratio and RNA quality indicator (RQI) were good predictors of severe total RNA
degradation, however, the greatest changes in the quantity of different mRNAs (FMR1, DNMT1, GUS, B2M and GAPDH) occurred
during the early to moderate stages of degradation; (ii) chromatographic features for the 18S, 28S and the inter-peak region
were the most reliable predictors of total RNA degradation, however their use for target gene normalization was inferior to
internal control genes, of which GUS was the most appropriate. Using GUS for normalization, we examined in the whole blood
the relationship between the FMR1 mRNA and CGG expansion in a non-coding portion of this gene, in a sample set (n = 30)
with the large variation in rRNA quality. By combining FMR1 3' and 5' mRNA analyses the confounding impact of mRNA
degradation on the correlation between FMR1 expression and CGG size was minimized, and the biological significance increased
from p = 0.046 for the 5' FMR1 assay, to p = 0.018 for the combined FMR1 3' and 5' mRNA analysis.
Conclusion: Our observations demonstrate that, through the use of an appropriate internal control and the direct analysis of
multiple sites of target mRNA, samples that do not conform to the conventional rRNA criteria can still be utilized to obtain
biologically/clinically relevant data. Although, this strategy clearly has application for improved assessment of FMR1 mRNA
toxicity in blood, it may also have more general implications for gene expression studies in fresh and archival tissues.
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Background
The mutations in an X linked FMR1 gene [1] have some
unique qualities. While large CGG expansions (>200) 3'
of its promoter give rise to fragile X syndrome – a neu-
rodevelopmental disorder caused by silencing of the gene,
smaller expansions (permutations – PM, 55–200 repeats)
lead to late onset pathologies through entirely different
mechanisms, involving a toxic gain of function of this
gene's transcripts [2-4]. Fragile X Tremour Ataxia Syn-
drome (FXTAS) is the most prevalent disorder associated
with PM alleles occurring in 50% of all older carrier males
[5]. It is progressive neurodegenerative disorder manifest-
ing with ataxia and/or intension or other tremors, cogni-
tive decline, psychiatric involvement and characteristic
MRI and histopathological features [5-8]. In females,
these alleles are associated with a significant increase in
premature ovarian failure [9]. A toxicity of an elevated
FMR1 mRNA which is believed to be pathogenic in these
conditions, has been supported in animal models where
it leads to increased cell death in Drosophila [10] and mice
[11]. Although, in humans the level of mRNA is usually
assessed in whole blood, there is a significant correlation
between FXTAS associated with these levels and the typi-
cal neurological [12], and psychiatric [13] manifestations.
This implies that the assessments of FMR1 mRNA levels in
carriers of small CGG expansions, apart from being essen-
tial in the mechanisms involved in RNA toxicity, may also
have a diagnostic and prognostic significance.
FMR1 expression is primarily regulated by the state of
methylation of its promoter. DNMT1 is an enzyme piv-
otal in this process [14-16]. This implies that DNMT1 may
be indirectly involved in the mechanisms leading to FMR1
related disorders. Thus, expression of both genes, FMR1
and DNMT1, is of interest in fresh and archival samples
from individuals with diseases characterized by abnormal
expansions within the CGG region. Unfortunately, archi-
val samples and samples extracted from blood have varia-
ble total RNA and mRNA degradation, which we have
found to be a confounding factor in the gene expression
analysis, unless a method was established to normalize
for FMR1 and DNMT1 mRNA degradation.
Previous real-time PCR studies normalized gene expres-
sion against total cell number, total RNA or mRNA of
internal control gene/s, reviewed in [17]. The main con-
straints associated with using total cell number for nor-
malization is that the RNA has to be of a very high quality
and the cell counts have to be accurate, which is not pos-
sible for solid tissues. Total RNA has been particularly use-
ful for normalization using absolute and relative standard
curve methods for real-time PCR, and has been shown to
produce biologically relevant and highly reproducible
data [18]. However, the most frequently applied normali-
zation method involves the use of internal control gene/s
based on the rational that the mRNA levels of these con-
trol genes in the tested samples should reflect the effect of
variables on the quantity and quality of the target gene
mRNA, and at the same time be minimally effected by the
tested variables [19,20]. Previous real-time PCR expres-
sion assays for FMR1 and DNMT1 have utilized GUS and
HPRT as internal control genes [2,21,22]. However, these
assays did not take into consideration the appropriateness
of these genes as controls in relation to the quantity and
quality of the starting material. A number of studies have
suggested that confirmation of total RNA quality prior to
real-time PCR quantification via capillary electrophoresis
is essential in obtaining meaningful gene expression data
[23].
In this study the Experion system (Bio-rad) was used to
assess the quality of rRNA by subjective/visual interpreta-
tion of the chromatographs for absence of peaks other
than those of 18S, 28S and 5S, and/or by examining the
28S:18S ratio and the RNA Qiality Indicator (RQI) values.
However, these approaches have their limitations which
we addressed in the study. We also evaluated in depth the
use of internal control genes and the capillary electro-
phoresis features for the normalization of mRNA degrada-
tion in partially degraded and intact RNA from patient
lymphoblasts and blood. We then defined the best predic-
tor of target gene mRNA degradation, utilizing it for nor-
malization in the whole blood RNA with a high variability
of rRNA quality. In this sample set we examined the rela-
tionship between the FMR1 mRNA and the CGG expan-
sion in a non-coding portion of this gene, and found that
by incorporating the 3' and 5' mRNA analysis data from
patients with small to intermediate CGG expansions, we
have significantly improved upon the current approach
used to examine the FMR1 mRNA toxicity, demonstrating
the clinical relevance of our strategy.
Methods
Cell Culture
Fourteen EBV transformed lymphoblast cell lines from
healthy controls (FMR1 alleles – 6 to 40 repeats); grey
zone carriers (41 to 55 repeats), premutation carriers (55
to 200 repeats) and full-mutation carriers (>200 repeats)
[24-26] were obtained from the MCRI tissue culture stor-
age repository, or purchased from Coriell (Table 1). The
cell-viability counts and cell composition were deter-
mined by trypan blue exclusion, using a hemocytometer.
Cells were plated at a density of 106 cell/ml in RPMI
medium (Sigma StLuis, MO, USA)/10% Foetal bovine
serum (CSL) at 37°C, 5% CO2 overnight. Cell pellets were
resuspended in RNA lysis buffer, (10 μl β-mercaptoetha-
nol/1 ml of RLT buffer from Qiagen, Hilden, Germany),
and stored at -80°C until RNA extraction.BMC Clinical Pathology 2009, 9:5 http://www.biomedcentral.com/1472-6890/9/5
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Degradation of total RNA
Total RNA was extracted and purified using the RNeasy
extraction kit (Qiagen Inc., Hilden, Germany). RNA con-
centrations were measured in triplicate using a NanoDrop
ND-1000 Spectrophotometer, with purity being deter-
mined by the A260/A280 ratio using the expected values
between 1.8 and 2. Each RNA sample was then diluted to
2 ng/ul. Sixty ul of each sample was left at room tempera-
ture for 0, 18, 24 and 96 hours. At each time point an aliq-
uot of 15 ul was collected from each sample, 5 ul of which
were used for capillary electrophoresis (Bio-rad) and 2 ul
for cDNA synthesis.
RNA samples from blood of CGG expansion carriers
The original study that investigated the relationship
between  FMR1  expression and CGG expansion was
approved by the La Trobe University Human Ethics Com-
mittee, the Southern Tasmanian Health and Medical
Human Research Ethics Committees, and by the Institu-
tional Review Board of the University of California at
Davis. The methods used for CGG repeat sizing and FMR1
mRNA assessments, as well as the results of correlation
between these two measures in a larger sample, which
included the present participants, were reported in the
earlier study [4]. An aliquot of total RNA was originally
isolated from 3 ml of peripheral blood using Tempus
Blood RNA tubes as previously described in: Loesch, et al.
(2007) [4]. After more than 1 year of storage at -80°C, the
total RNA quality was assessed using capillary electro-
phoresis. All samples were diluted to 5 ng/ul, prior to
reverse transcription. Here we utilized these earlier data
on CGG repeat size, but validated and conducted new
assays on the expression of FMR1ex3.4, FMR1ex13.14 and
GUS.
Capillary electrophoresis
Total RNA quality was assessed using the RNA HighSens
Kit as per manufacturer's instructions (Bio-rad). Objective
and subjective analysis of each RNA profile was per-
formed. Objective assessment involved automatic collec-
tion of a number of (manually set) parameters which
included percentage area under the lower marker (LM),
small fragment region (SR), 5S, fast region (FR), 18S, Inter
region (IR), 28S, post region (PR), the 28S:18S ratio and
RQI (Figure 1A). Subjective assessment (Figure 1B and
1C) involved descriptive comparison of chromatographic
Table 1: Cell Line Details
RNA ID: MCRI Cell Line ID: Source: CGG repeat number Classification
489 CL880207 MCRI TC. 30 Healthy control male
491 CL0050251 Corriell; GM07174A 30 Healthy control male
492 CL860012 MCRI TC. 30 Healthy control male
488 CL860021 MCRI TC. 30 Healthy control male
494 CL920415 MCRI TC. 31 Healthy control male
584 CL0070217 MCRI TC. 47 Grey zone male
585 CL0070183 MCRI TC. 41 Grey zone male
493 CL0050250 Corriell; GM07174A 103 Premutation male
497 CL0060293 MCRI TC. 170 Premutation male
496 CL970149 MCRI TC. 50; 100 Premutation female carrier
487 CL0050246 Corriell; GM07537A 29; 370 FRAX female carrier
498 CL850085 Corriell; GM4025A 490 FRAX male
586 CL850084 Corriell; GM3200A 530 FRAX male
495 CL840159 MCRI TC. 563; 47 FRAX female
*MCRI TC – Murdoch Childrens Research Institute Tissue Culture Repository.BMC Clinical Pathology 2009, 9:5 http://www.biomedcentral.com/1472-6890/9/5
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features based on previous publications using this system
[27].
Reverse Transcription Real-time PCR
Reverse transcription was performed one reaction per
sample using the Multiscribe Reverse Transcription Sys-
tem, 50 units/ul (Applied Biosystems). The 7900HT Fast
Real Time PCR (Applied Biosystems) was used to quantify
FMR1ex3.4, FMR1ex13.14, DNMT1, GAPDH, B2M, and
GUS, using the relative standard curve method. The target
gene and the internal control gene dynamic linear ranges
were performed on a series of doubling dilutions of RNA
(160-0.5 ng/ul) of a selected peripheral bood mononu-
clear cell sample. Previously published sequences were
used for RT-PCR primers and TaqMan probe for:
FMR1exon3/4 and GUS [2]; FMR1exon13/exon14 [21], and
DNMT1 [22]. FMR1exon3/4, FMR1exon13/14 and DNMT1
primers and probes were used at concentrations of 18 uM
and 2 uM, respectively. GAPDH and B2M primer/probe
mixes were obtained from PrimerDesign (PerfectProbe ge-
PP-12-hu kit) and used at concentration of 2 uM. Each
sample was assayed in duplicate 10 μl PCR reactions, con-
sisting of 5.8 mM MgCl2, 1 μl Buffer A (Applied Biosys-
tems), 3.35 μl RNase-free water, 1.2 mM dNTPs, 0.01
units/μl of AmpliTaq Gold, 0.5 μl of TaqMan probe and
0.5 μl forward and 0.5 μl reverse primers, and 1 μl of the
Assessment of chromatograms for total RNA degradation Figure 1
Assessment of chromatograms for total RNA degradation. (A) Objective assessment – (manually set parameters) 
included percentage area under the lower marker (LM), small fragment region (SR), 5S, fast region (FR), 18S, the inter-peak 
region (IR), 28S, post region (PR) and the 28S/18S ratio. () defines the boundary of each of the regions. (B) Subjective assess-
ment of the same sample before (blue) and after (red) being degraded at room temperature. The typical features included 
increase in baseline (primarily IR), decrease in 28S% area, 28S:18S ratio and RQI. (C) Subjective assessment of the same sample 
moderately (red) and highly (blue) degraded at room temperature. The typical features included increase in the baseline (FR, 
IR, SR), increase in 5S, and decrease in 18S% and 28S% areas as well as the 28S:18S ratio and RQI.
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reverse transcription (cDNA) reaction. The annealing tem-
perature for thermal cycling protocol was 60°C for 40
cycles. Samples were quantified in arbitrary units (au) in
relation to the standard curves performed on each plate.
Statistical analysis
Generalized estimating equations (GEE) were used for the
objective assessment of the chromatographs and mRNA
integrity. Normalization of FMR1 and DNMT1 mRNA to
18S, 28S, GAPDH and GUS, expressed as a function of the
degradation time, was assessed by fitting the values to a
simple linear regression. The sign test was then used to
examine the null hypothesis that the median slope was
zero against the two-sided alternative of it not being equal
to 0. The relationship between the qPCR results for
FMR1ex3.4 and FMR1ex13.14 assays with the CGG expan-
sion size was assessed using a significance test in a linear
regression. The analysis was conducted using the publicly
available R statistical computing package, version 1.191
(R development Core team, 2004).
Results
Subjective assessment of chromatographs and mRNA 
integrity of FMR1 and DNMT1
FMR1  and  DNMT1  mRNA quantities were examined
using the relative standard curve method, in RNA samples
496, 497, 488, 584 and 585 artificially degraded at room
temperature for 0, 18, 24 and 96 hours from 5 lymphob-
last cell lines (Table 1). The samples were subjectively
assessed as described in Figure 1 for the relationship
between the capillary electrophoresis profiles and mRNA
quantities of FMR1 (5' and 3') and DNMT1 (Figure 2).
Sample 496 (Figure 2; Panel I) displayed minor differ-
ences in the capillary electrophoresis profiles between 0
and 24 hours, with the most prominent change being
observed between 24 and 96 hours (a large increase in the
inter-peak area and the fast region, and a marked decrease
in the 28S peak). This was also reflected in the 28S:18S
ratios and RQI values, where there was no change between
0 and 24 hours, but a large decrease between 24 and 96
hours. In contrast, FMR1ex13.14 mRNA level decreased by
more than half within the first 18 hours and remained at
this level for the following time points. A similar trend
was observed for FMR1ex3.4  mRNA, which decreased
between 18 and 24 hours of incubation, and remained at
the same level through to 96 hours. In contrast, there were
no major changes in DNMT1 mRNA quantities for sample
496 throughout the time course.
Sample 497 was different to all the other RNA examined,
as it displayed a second, smaller 28S peak at 0 hours (Fig-
ure 2; Pannel II E). The origin of this peak, which has been
previously reported using the analogous system
(Schroeder et al.; United states patent publication 2006/
0246577 A1) is unknown; the absence of any other RNA
degradation markers such as an increase in the inter-peak
area and/or the fast region argue against a plausible expla-
nation that it could represent 28S rRNA degradation. It is
also unclear why a significant change in the capillary ele-
crophoresis profile for this sample was observed at 18
hours, when the larger 28S peak(s) almost completely dis-
appeared (Figure 1, Panel II F), while at 24 hours there
was an increase in the 28S:18S ratio and RQI (Figure 1,
Panel II F and G). This may be linked to the structure of
the anomolous 28S peak, the unusual integrity of which is
beyond the scope of this study. Interestingly, the mRNA
levels for FMR1 and DNMT1 did not change between 0
and 18 hours. The greatest increase in total RNA degrada-
tion of sample 497 was observed between 24 and 96
hours, as indicated by a significant increase in the inter-
peak area and the fast region and a marked decrease in the
28S:18S ratio and the RQI value (Figure 2, Panel II G and
H). However, again this trend was not mirrored by the
degradation of FMR1 and DNMT1 mRNA, which showed
no major differences between 24 and 96 hours.
For the sample 488, within the first 18 hours there was no
difference in RQI, however the 28S:18S ratio decreased
from 2.5 to 1.57, with a slight increase in the inter-peak
area within the first 18 hours (Figure 2, Panel III, I and J).
At 24 and 96 hours we observed a further decrease in the
28S:18S ratio which was mirrored by a moderate decrease
in RQI, and a prominent increase in the inter peak area
and the fast region (Figure 2, Panel III, K and L). In con-
trast, there was only a slight decrease in DNMT1 mRNA
level within the first 18 hours, which remained at the
same level for the following time points.
Samples 584 and 585 demonstrated similar kinetics of
total RNA degradation. At 0 hours these samples had sim-
ilar RQI values, but different 28S:18S ratios (Figure 2,
Panels IV and V). A striking increase in total RNA degrada-
tion was observed between 24 and 96 hours. During this
period for sample 584 the 28S:18S ratio dropped from 1.2
to 0, and RQI from 9.3 to 2.9 (Figure 2, Panels IV; O and
P), while for sample 585 the 28S:18S ratio dropped from
1.64 to 0.77, and RQI from 9.7 to 7.7 (Figure 2, Panel V;
S and T). This was related to a significant increase in the
inter peak area and the fast region. In contrast, mRNA
quantities of FMR1ex3.4  and  FMR1ex13.14  were
decreased by approximately half between 0 and 18 hours
in both samples 584 and 585, and for DNMT1 in sample
584 about 3 fold between 0 and 24 hours.
The similarities in FMR1 mRNA and total RNA degrada-
tion kinetics in both 584 and 585 samples may be related
to these cell lines harbouring grey zone alleles, whereas
samples 496 and 497 that showed different degradation
kinetics were from premutation carriers (Table 1).BMC Clinical Pathology 2009, 9:5 http://www.biomedcentral.com/1472-6890/9/5
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Although, an in-depth investigation of this relationship is
beyond the scope of this manuscript, the differences in
FMR1ex3.4 mRNA degradation kinetics between the pre-
mutation and grey zone cell lines (Figure 2) were consist-
ent with previous studies showing that the increased
length of the CGG tract correlates with increased mRNA
stability through hairpin formation within the 5'UTR
repeat region [28].
Together these data suggested that the total RNA degrada-
tion rate moderately varies between the samples from dif-
ferent cell lines with the most prominent changes being
observed between 24 and 96 hours. This was poorly cor-
related with the profile of FMR1 and DNMT1 mRNA deg-
radation that predominantly occurred within the first 18
to 24 hours, indicating that there was no clear correlation
between the rate of total RNA degradation from the sub-
jective assessment of the chromatographs and mRNA deg-
radation as determined by real-time PCR. Because FMR1
mRNA stability may be related to the size of the CGG
repeat within its UTR and the pathology of FMR1 related
disorders [28], in the following sections we have estab-
lished a method to normalize for mRNA degradation
independent of the CGG expansion size, so that the clini-
cal relevance of the CGG related FMR1 mRNA toxicity can
be identified in samples with variable rRNA quality.
Relationship between subjective assessment of chromatograms for total RNA degradation and quantification of FMR1 and  DNMT1 mRNA, using real-time PCR Figure 2
Relationship between subjective assessment of chromatograms for total RNA degradation and quantification 
of FMR1 and DNMT1 mRNA, using real-time PCR. RNA samples from 5 lymphoblast cell lines were degraded at room 
temperature for 0 hr (A, E, I, M, Q), 18 hrs (B, F, J, N, R), 24 hrs (C, G, K, O, S), and 96 hrs (D, H, L, P, T), and assessed for 
total RNA integrity using Experion capillary electrophoresis ststem. Panels I-IV – RNA samples 496, 497, 488, 584, and 585, 
respectively. () defines the boundary of each of the regions (see Figure 1). FMR1ex3/4, FMR1ex13/14 and DNMT1 mRNA 
arbitrary quantities were determined using real-time PCR relative standard curve method. Samples with the coefficient of vari-
ance greater than 30% between the duplicate reactions were omitted from the analysis.
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Objective assessment of the chromatographs and mRNA 
integrity
Objective assessment of total RNA and mRNA degrada-
tion was performed in RNA samples from 14 cell lines
(Table 1). Ten features were measured from each chroma-
tograph and 6 variables measured using real-time PCR
from the corresponding cDNA samples at 4 paired time
points. The RNA from three fragile X cell lines were
excluded from the FMR1 real-time PCR analysis for the
RNA degradation study, as they had no FMR1 expression.
The first aim of this approach was to objectively delineate
which features of the chromatographs and gene expres-
sion profiles (GAPDH, B2M, GUS) could be used as pre-
dictors of the total RNA degradation as reflected by the
degradation time. The second aim was to objectively
delineate whether FMR1 and DNMT1 mRNA degradation
correlated with the degradation time, and if not, which
features could be used as predictors of the target gene
mRNA integrity.
Based on the subjective assessment, we arbitrarily divided
the degree of total RNA degradation into four categories:
0 hours – intact; 18 hours – early degradation; 24 hours –
moderate to severe degradation; 96 hours – severe degra-
dation, under the assumption that RNAs from different
cell lines follow this progressive trend of degradation at
the four time points. GEE were then utilised to provide an
estimation of which parameters most closely reflected
FMR1 and DNMT1 mRNA integrity in early versus moder-
ate versus late degradation stages, and through the time
course as a whole.
As expected, the most significant predictors of total RNA
degradation from the combined and individual compari-
sons of chromatographic features were the percentage
areas of 18S, 28S and the inter-peak region (Table 2).
These features appeared to be suitable predictors of early,
moderate and severe RNA degradation (p < 0.001). In
contrast, 5S % area was a good predictor of only early to
moderate RNA degradation (p < 0.05), and the small frag-
mentation region percentage area of moderate to severe
RNA degradation (p < 0.05). However, the most promi-
nent predictors of severe RNA degradation were the fast
region % area (p < 0.001), the 28S:18S ratio (p < 0.001),
the RQI (p < 0.001) and the lower marker % area (p =
0.072). Interestingly, in contrast to the 28S:18S ratio and
the lower marker % area, the RQI could be also used as a
predictor of moderate degradation (p < 0.05). The post
region % area was the only parameter that was not associ-
ated with any stage of RNA degradation.
GUS  and  GAPDH  mRNA degradation closely reflected
moderate to severe degradation of total RNA (p < 0.001),
best represented by the small fragmentation region %
area. In contrast, B2M mRNA could only be used to pre-
dict early total RNA degradation (p = 0.093). Further-
more, it was not associated with any other
chromatographic and gene expression parameters exam-
ined. For the target transcripts, DNMT1 and FMR1ex3/4,
mRNA degradation was closely associated with moderate
to severe degradation of total RNA (p < 0.001), and was
best predicted by the small fragmentation region % area,
and by GUS and GAPDH mRNA, all of which had similar
degradation kinetics. In contrast, FMR1ex13.14  mRNA
degradation appeared to be closely associated with early,
moderate and severe total RNA degradation (p < 0.001),
and was best predicted by % areas of 18S, 28S and the
inter-peak region (p < 0.001). This analysis demonstrated
that the degradation of mRNA was different between most
internal controls and target genes examined, and that the
degradation kinetics of specific mRNAs were not necessar-
ily the same as those for total RNA and rRNA.
Assessment of FMR1 and DNMT1 mRNA normalized to 
capillary electrophoresis and real-time PCR predictors of 
mRNA degradation
The target gene expression in the RNA samples from the
cell lines were normalized to the best predictors of FMR1
and DNMT1  mRNA degradation as determined by the
objective assessment of chromatographs and mRNA
integrity. 18S % area, 28S % area, GUS mRNA or GAPDH
mRNA quantity were used for normalization, and
expressed as a function of the degradation time. The nor-
malization method that provided the most constant (least
significant) values throughout the time course was con-
sidered as the most optimal of the predictors tested for the
target gene mRNA degradation (Figure 3; the sign test was
used to examine the null hypothesis that the median slope
was zero against the two-sided alternative of it not being
equal to 0). We found that for DNMT1 both 18S (p =
0.066) and 28S (p = 0.066) % area were poor normaliza-
tion features compared to GAPDH (p = 0.388) and GUS
(p = 0.774). Similarly, for FMR1ex3.4, both 18S (p = 0.11)
and 28S (p = 0.11) % area normalization provided less
constant values than GAPDH (p = 0.51) and GUS (p =
0.254). For FMR1ex13.14, 18S (p = 0.11) and 28S (p =
0.11) % area as well as GAPDH (p = 0.11) normalization
provided less constant values than GUS (p = 0.34). Thus,
it appeared that normalization of the target genes to 18S
and 28S chromatographic features was overall inferior to
the use of internal control genes, GAPDH  and  GUS.
Although 18S and 28S % areas could be still be used as
normalization markers for FMR1ex3.4 and FMR1ex13.14,
the most optimal of the predictors tested for both DNMT1
and FMR1 was GUS.BMC Clinical Pathology 2009, 9:5 http://www.biomedcentral.com/1472-6890/9/5
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Table 2: Correlation of RNA degradation time with capillary electrophoresis features and mRNA quantities
RNA feature Predominant size of
RNA detected and
amplicon length
(for mRNA only)
0 to 18 hours 
comparison
p values
0 to 24 hours 
comparison
p values
0 to 96 hours 
comparison
p values
Combined 
comparison
p values
18S % of total area 
(n = 53)
1700 bp 0.001*** 0.001*** 0.001*** 0.001***
28S % of total area 
(n = 53)
3770 bp 0.001*** 0.001*** 0.001*** 0.001***
5S % of total area 
(n = 53)
160 bp 0.043** 0.001*** 0.386 0.001***
Fast region % of total 
area (n = 53)
____ 0.717 0.92 0.001*** 0.001***
Inter-peak region % of 
total area (n = 53)
____ 0.001*** 0.001*** 0.001*** 0.001***
Post region % of total 
area (n = 53)
____ 0.36 0.16 0.316 0.42
Lower Marker % of 
total area (n = 53)
____ 0.256 0.322 0.072* 0.001***
Small fragmentation 
region % of total area 
(n = 53)
____ 0.12 0.046** 0.074* 0.026**
28S:18S ratio (n = 53) ____ 0.553 0.082* 0.001*** 0.001***
RQI ____ 0.223 0.024** 0.001*** 0.001***
DNMT1 mRNA 
(au) (n = 41)
5084 bp – 142 bp 0.173 0.006** 0.004** 0.001***
FMR1ex.3.4 mRNA 
(au) (n = 43)
4350 bp – 122 bp 0.265 0.001*** 0.001*** 0.003**
FMR1ex13.14 mRNA 
(au) (n = 43)
4350 bp – 89 bp 0.024** 0.013** 0.012** 0.001***
GUS mRNA 
(au) (n = 52)
2200 bp – 80 bp 0.169 0.001*** 0.001*** 0.001***
B2M mRNA 
(au) (n = 35)
976 bp – 114 bpo 0.093* 0.13 0.571 0.01**
GAPDH mRNA 
(au) (n = 52)
1310 bp – 110 bp 0.117 0.001*** 0.001*** 0.001***
*Generalized estimating equations (GEE) were used. Data from samples with different levels of total RNA degradation (early, moderate, high) are 
shown as the p-values of the chi square test (p < 0.1*; p < 0.05**; p < 0.001***) and the sample size (n).BMC Clinical Pathology 2009, 9:5 http://www.biomedcentral.com/1472-6890/9/5
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Combining the analysis of 3' and 5' mRNA sites and GUS 
normalization minimizes the confounding impact of mRNA 
degradation in RNA samples from whole blood with highly 
variable rRNA quality
We have previously demonstrated using freshly extracted
RNA, that FMR1 expression was significantly elevated in
carriers of CGG expansion, compared with normal con-
trols of a similar age, and that the expression was propor-
tional to the size of CGG expansions within the grey zone
and lower premutation range [4]. Subsequent analysis of
these stored samples revealed a high variability in rRNA
quality, which posed major confounder concerns. We
have therefore determined whether these samples could
provide clinically relevant data using the normalization
criteria tested in the study.
The FMR1ex3.4/GUS mRNA levels assessed here closely
corresponded to the levels of the earlier study in freshly
extracted RNA samples[4], but using the relative standard
curve as opposed to the delta-Ct method. As expected we
have also found a significant correlation (p = 0.028)
between the FMR1ex3.4/GUS  and  FMR1ex13.14/GUS
assays indicating that most samples had intact FMR1
mRNA (Figure 4A) despite the observed variability in
rRNA quality as exemplified by the chromatographs of
samples 350 and 351, with the 28S:18S ratio between 2.1
Normalization of FMR1 and DNMT1 mRNA to 18S, 28S, GAPDH and GUS, expressed as a function of degradation time Figure 3
Normalization of FMR1 and DNMT1 mRNA to 18S, 28S, GAPDH and GUS, expressed as a function of degrada-
tion time. Each sample (listed in Table 1) is represented by a differently colored line whose number varied between 8 and 14 
for the nine plots; depending on completeness of the data set for the variables examined. (A) DNMT1 mRNA normalized to 
18S (p = 0.066), 28S (p = 0.066), GAPDH (p = 0.388), GUS (p = 0.774); (B) FMR1ex3.4 mRNA normalized 18S (p = 0.11), 28S (p 
= 0.11), GAPDH (p = 0.51), GUS (p = 0.254); (C) FMR1ex13.14 mRNA normalized 18S (p = 0.11), 28S (p = 0.11), GAPDH (p = 
0.11), GUS (p = 0.34).BMC Clinical Pathology 2009, 9:5 http://www.biomedcentral.com/1472-6890/9/5
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and 0.4, and RQI between 9.1 and 3.8 (Figure 4C and
4D). We have also found a significant linear correlation
between  FMR1ex3.4/GUS  mRNA levels and the CGG
expansion size, (p = 0.046) (Figure 4B) indicating the bio-
logical relevance of the data. However, there was no sig-
nificant correlation between FMR1ex13.14/GUS  mRNA
levels and the CGG expansion size (p = 0.1) (Figure 4B).
A number of samples (samples 339, 354, 358 and 360 –
colour coded), did not follow the common pattern of cor-
relation between the FMR1ex3.4/GUS and FMR1ex13.14/
GUS  assays (Figure 4A), and the FMR1ex3.4/GUS  and
FMR1ex13.14/GUS assays with the CGG expansion size
(Figure 4B). Two of these samples, 339 and 360 were also
outliers for rRNA quality assessment with the 28S:18S
ratios of 3.3 and 0.24, and RQI values of 10 and 3, respec-
tively (Figure 4D). Furthermore, there was no uniform
correlation between rRNA integrity and FMR1  mRNA
quality for both the FMR1ex3.4/GUS and FMR1ex13.14/
GUS  assays in these samples. Each of these samples
appeared to be significantly affected at either the 5' or 3'
sites (Figure 4A, B and 4C). Only one sample (360), with
poor rRNA profile, appeared to have FMR1 mRNA integ-
rity compromised at both the 5' and 3' sites (Figure 4B and
Relationship between FMR1 mRNA degradation, rRNA integrity and biological relevance of expression data in RNA samples  from patient whole blood (n = 30) with CGG expansion between 20 and 55 CGG repeats Figure 4
Relationship between FMR1 mRNA degradation, rRNA integrity and biological relevance of expression data in 
RNA samples from patient whole blood (n = 30) with CGG expansion between 20 and 55 CGG repeats. (A) 
Relationship between qPCR results for FMR1ex3.4 (x axis) and FMR1ex13.14 assays (y axis) standardized to GUS. (B) Relation-
ship between CGG expansions (x axis) and qPCR results standardized to GUS (y axis) for FMR1ex3.4 and FMR1ex13.14 assays 
separately and combined. (C) Representation of proposed locations for mRNA breaks and loss of molecules for qPCR (\\) 
within product sequences of both assays for color coded representative samples (350 and 351) and outliers (339, 360, 354 and 
358). (D) Chromatographs, 28S:18S and RQI values for color coded samples (each dot of the same color represents the same 
sample).
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4D). The confounding impact of these outliers was mini-
mized when the data for the FMR1 mRNA 3' and 5' end
analyses were combined, as the significance of the FMR1
correlation with CGG expansion size increased to p =
0.018.
Discussion
The specific aim of this study was to establish an optimal
method to normalize for the degradation of target gene
FMR1 mRNA in a sample set showing large variability in
rRNA quality, and demonstrate it's clinical/biological rel-
evance. Previous studies have normalized FMR1 expres-
sion to GUS  [2,21]. However, we questioned the
appropriateness of GUS  as an internal control for our
sample set, where we have observed a large variation in
rRNA degradation, particularly as there are no previous
studies that examined the rates of mRNA degradation for
both  FMR1  and  GUS. Since different mRNA species
degrade depending on their length and secondary struc-
ture [18,23,29], we assessed if GUS was a suitable control
for FMR1 mRNA degradation, and if not, which of the
capillary electrophoresis and real-time PCR parameters
would provide a better normalization method. Because of
the potential relevance of DNMT1 to FMR1 gene regula-
tion [30-33], we have included a parallel analysis of
DNMT1 as as target gene in some of the studies.
We initially demonstrated using the Experion system that
for the artificially degraded RNA samples, both the
28S:18S ratio and the RQI were most useful as predictors
of severe RNA degradation, whereas the greatest changes
in stability of different transcripts examined occurred dur-
ing early to moderate stages of RNA degradation. Thus,
the 28S:18S ratio and the RQI were not suitable predictors
of mRNA stability, at least in our settings. Since, the RQI
is closely related to a more widely used RNA Integrity
Number (RIN) from an analogous Agilent system (Bio-
Rad electrophoresis technical note 5761), our findings
suggest that RIN may be also inappropriate as a normali-
zation tool in our settings. Furthermore, the subjective
assessment of general chromatographic features did not
provide a useful estimation of mRNA degradation, as real-
time PCR could still be used to obtain biologically rele-
vant mRNA data in samples with chromatographs indicat-
ing severe rRNA degradation. In another approach, we
determined that of the 10 selected chromatographic fea-
tures, 18S, 28S and the inter-peak region % areas were the
most reliable predictors of total RNA degradation when
examined as a function of the degradation time. However,
the normalization of the target genes to 18S and 28S chro-
matographic features was found to be inferior to the use
of the internal control genes.
Primarily these observations indicate that the degradation
kinetics of rRNA may be heavily size dependent, as the
small 5S rRNA subunit, 160 nucleotides, was found to be
a good predictor of only early to moderate RNA degrada-
tion, whereas the 18S and 28S % areas, 1770 and 3770
nucleotides respectively, could be used to predict RNA
degradation at early, moderate and late stages of degrada-
tion. For mRNA quantitation, by qPCR, however, it has
been previously suggested that the length of the amplicon,
rather than that of the whole mRNA molecule, may be a
more important indicator of degradation kinetics, partic-
ularly because fragmentation of a long mRNA may only
result in a loss of the molecule for qPCR detection if the
RNA break occurs within the product sequence [23].
We've found that the location of the amplicon, may be
just as important as the size in determining the effect of
mRNA degradation on qPCR performance. This was ini-
tially observed by examining the differences in FMR1ex3.4
(5') and FMR1ex13.14  (3') qPCR data throughout the
RNA degradation time course. Since most FMR1  tran-
scripts contain the 195-bp exon 14 [34], and all contain
exons3/4, both assays target FMR1 transcripts of a similar
size and abundance, which is experimentally reflected by
the highly significant correlation between the two assays
for high quality total RNA samples from the peripheral
blood of patients with small to intermediate size expan-
sions (Additional file 1). Since the amplicons for both
assays are also of a similar size, if the location of the
amplicon is unimportant in determining RNA degrada-
tion kinetics, its effects should be similar on the qPCR
results for both assays. However there were clear differ-
ences between the 5' and 3' FMR1 results for the sample
set with the high variability in total RNA quality, which
may be explained by the 3' alternative splice site being
more susceptible to RNA breaks than the 5' common
region. Thus, thermal stress at the 3' site may result in the
loss of more molecules for qPCR detection, than that at
the 5' site, which is consistent with our findings in the
RNA samples extracted from whole blood where RNA
degradation had far less impact on the biological signifi-
cance of the FMR1ex3.4 data than on the FMR1ex13.14
results (Figure 4B).
We have also found that due to the differences between
degradation kinetics of mRNA and rRNA, normalization
of target mRNA levels using rRNA profiles, as indicated by
capillary electrophoresis, was inferior to the use of the
internal control genes. Therefore, we proposed an alterna-
tive approach, independent of capillary electrophoresis,
where by targeting each transcript at multiple sites for
qPCR analysis, the confounding impact of mRNA breaks
at any specific location on qPCR performance can be min-
imized. Specifically, in a previous study we've found that
the FMR1 mRNA levels were proportional to the size of
CGG expansions within the grey zone and lower PM range
[4]. In 30 of the original samples we've found the rRNABMC Clinical Pathology 2009, 9:5 http://www.biomedcentral.com/1472-6890/9/5
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quality to vary significantly. Half of the samples would
have had to be omitted from further analysis unless an
alternative method to capillary electrophoresis was found
to normalize for mRNA degradation.
We examined FMR1 expression in these samples without
omission by targeting FMR1 transcript at 5' and 3' ends
standardized to GUS, as we have shown that this strategy
is superior to the use of rRNA profiles from the capillary
electrophoresis analyses of the artificially degraded sam-
ples. Of the 30 samples we found four outliers that had a
significant impact on qPCR performance particularly for
the 3' FMR1ex13.14 assay. In 3 out of the 4 outliers this
was not directly related to rRNA quality. By combining
FMR1 mRNA 3' and 5' end analyses, the confounding
impact of these outliers on the correlation between FMR1
expression and CGG size was minimized, and the statisti-
cal significance of the data doubled.
Conclusion
In summary, we have demonstrated that in artificially
degraded RNA samples a number of chromatographic fea-
tures including 18S, 28S, the inter-peak region, the
28S:18S ratio and RQI can be used as predictors of differ-
ent stages of total RNA degradation. However, their use
for normalization of target gene mRNA degradation was
inferior to the use of internal control genes, of which GUS
was the most appropriate as it closely reflected the target
gene mRNA degradation kinetics. For the target FMR1
mRNA we've shown that the location of the amplicon,
may be just as important as the size of its transcript in
determining the effect of mRNA degradation on qPCR
performance. Furthermore, we've found that by targeting
the FMR1 transcript at multiple sites, the confounding
impact of mRNA breaks due to fragmentation within any
specific qPCR product sequence, and the subsequent loss
of mRNA molecules for qPCR detection, was minimized.
In clinical practice, this approach may be extremely use-
ful, as there is extensive variation in the time lapse
between the blood collection and RNA extraction for dif-
ferent samples, which contributes variation in rRNA and
mRNA quality. Our strategy allows for a more accurate
comparison between samples without sample loss.
Whilst we have shown that this approach is applicable for
the FMR1 mRNA in RNA extracted from whole blood in
our patient subset, there are also potential implications
on the development of diagnostic tests for the levels of
FMR1 mRNA toxicity associated with a number of clinical
conditions [2-9,12,13]. These findings are also likely to
have a broader application to expression studies of other
genes using precious archival or fresh blood samples with
a large variation in rRNA quality where sample omission
is not an option. More importantly, the approach pre-
sented in this manuscript may be useful to any diagnostic
application where mRNA integrity may be compromised
[35], including future developments of methods for detec-
tion of placental mRNA in maternal plasma, foetal RNA
markers for non-invasive prenatal diagnosis of pregnancy
associated diseases and foetal chromosomal aneuploi-
dies, as well as clinical uses of plasma or whole blood
RNA for detection of tumour RNA in cancer diagnostics.
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